|Day Low/High||106.93 / 108.27|
|52 Wk Low/High||61.61 / 115.14|
These companies have spent the last six months preparing for a second lockdown betting it will occur.
Right now, the market is furiously trying to price in a Blue Wave, and the health care sector is getting clobbered. But here's how I think things play out.
Diagnostics revenue grew an impressive 38% due to the necessity of Covid-19 testing.
There is a presidential debate on Thursday. The market is being forced to adjust for renewed potential uncertainty.
I don't pick stocks on politics, but was shocked to see how a majority of our Action Alerts PLUS holdings would perform if Joe Biden wins the White House.
New rapid tests and the effectiveness of universal mask wearing give hope while we wait on the elusive vaccine.
People want to wait and see on this beleaguered aviation name, but I don't think you can do that. Here's why.
Neither candidate seems to be the enemy of the market -- at least not yet.
Abbott Labs can bring back some normalcy to this country -- and the world -- with its BinaxNOW rapid antigen test along with its amazing Navica app.
AbbVie stock is a rare combination of value, growth, and yield, making it a unique pick in the health care sector.
We grade Choice Hotels, Hilton and Marriott, and check on the opportunities each offers.
Here's what I expect to happen to the market near term off this potentially game-changing development.
ABT will end the issues of flying and cruising. Of course it's another story when you get there. But boarding will be solved.
These companies will benefit immensely as the country experiences a burst of economic growth.
There is major rotational action taking place but the flood of liquidity is preventing any real downside from developing.
Plus, Veeva Systems reports stellar results and ups its guidance.
Speculative trading in lower-priced stocks has dried up and the small caps have been much tougher.
As the president pins all hopes on a Covid vaccine and shuns tried-and-true prevention efforts, Abbott is offering a rapid test that could be a game changer.
One is Abbott Labs' announcement of a quick and cheap Covid test.
Here's where ABT could be headed next.
It isn't just valuation that is likely to drive rotational action.
Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.
Let's go over five excuses so you know and are armed with them when they are used and make you faint and weak-handed.
All we have to do is take our cue from companies that boosted their forecasts but their stocks did nothing.
Next week the June quarter earnings season maelstrom kicks off with 115 companies, including 32 S&P 500 constituents, reporting their latest quarterly results. In recent days we've seen a number of companies up their outlook for the quarter but we'v...
I would wait until the next down day, and there will be one.